LifeVantage Corporation (Nasdaq: LFVN) reported financial results of $61.2 million for its second quarter ended December 31, 2019.
The company reported a revenue increase of 5.3 percent as compared to $58.2 million in the second quarter of fiscal 2019.
- Revenue in the Americas for the second quarter increased 4.3 percent compared to the second quarter of fiscal 2019 and
- Revenue in the Asia/Pacific and Europe region increased 7.8 percent—including 4.7 percent growth in Japan—compared to the second quarter of fiscal 2019.
- Total active accounts increased 0.6 percent sequentially to 182,000, while declining year over year by 1.1 percent.
“We are pleased with our strong revenue growth and profit performance during the second quarter,” said LifeVantage President and Chief Executive Officer Darren Jensen. “We generated over 5 percent year over year revenue growth, 82 percent year over year growth of adjusted EBITDA and 138 percent adjusted EPS growth over the prior year period.
Jensen noted the U.S. launch of the company’s newest addition to its flagship Protandim® product line, Protandim® NAD Synergizer™, was a significant success and lifted sales across the entire family of Protandim® products during the quarter. Additionally, the company saw strong sales growth in our Asia Pacific and Europe region and enjoyed a strong launch in New Zealand during the quarter, leveraging existing business in Australia.
For the first six months of fiscal 2020, LifeVantage reported revenue of $117.5 million, an increase of 3.2 percent as compared to $113.8 million for the first six months of fiscal 2019. Revenue in the Americas for the first six months of fiscal 2020 increased 1.1 percent compared to the first six months of fiscal 2019 and revenue in the Asia/Pacific and Europe region increased 9.1 percent compared to the first six months of fiscal 2019.
To read the full LifeVantage Q2 2020 financial report, click here.
